6月18日下午，中巴制药、医疗保健及生物技术商务洽谈会在巴基斯坦驻华大使馆举行。本次活动由巴基斯坦驻华大使馆主办，中国产业海外发展协会协办。巴基斯坦驻华大使卡里尔·哈什米、中国产业海外发展协会常务副秘书长蒋赟出席会议并致辞。
作为中巴建交75周年系列经贸配套活动之一，本次会议亦为7月卡拉奇中巴医药制造与投资B2B大会预热。活动吸引了复星医药奥鸿药业、普乐医疗、华辉安健、北京盈科瑞瑞创新医药、阳光诺和、河北紫薇山制药、陕西诺兴等44家国内医药、器械及生物科技领军企业参会，各方围绕原料药、生物制剂、疫苗、医疗器械及中医药等全产业链，深度挖掘赴巴投资新机遇。
哈什米大使在致辞中全面阐述了巴基斯坦医药产业的投资红利。他指出，巴基斯坦拥有超2.5亿人口的广阔市场，医药年产值突破40亿美元，增速稳定在10%-12%。他强调，中国目前满足了巴方85%-90%的原料药及95%的疫苗需求，双方产业互补性极强，诚挚欢迎中国企业赴巴设厂，依托巴基斯坦辐射南亚、中亚、中东及非洲的区位优势，共享巨大市场潜力。
蒋赟常务副秘书长在致辞中表示，中巴全天候战略合作伙伴关系为产业合作奠定了坚实基础。中国拥有全球最完整的医药产业链，与巴基斯坦的人口红利及产业升级需求高度契合，双方在原料药贸易、联合注册、中医药合作及合资建厂等领域已积累成熟经验。作为国家级出海服务平台，中海协将持续发挥桥梁作用，为企业提供涵盖市场调研、政策解读、资源匹配及风险防范的全链条服务，推动双边合作从单一产品出口向“技术+产能+品牌+服务”的深度协同模式转型。
会议期间，巴使馆投资贸易专员阿亚兹·穆罕默德进行了专项推介，详细解读了市场准入标准、外资扶持政策及出口退税等实操细则，并就建厂流程、注册周期等企业关切的问题现场答疑。随后，参会企业分两轮进行了高效交流对接。
本次使馆专场洽谈会权威性强、对接精准，使企业得以一站式获取巴方官方一手政策与市场数据。借助中海协搭建的高效对接平台，企业不仅有效降低了出海成本，更显著增强了投资信心。下一步，中海协将紧密跟进各项合作意向，助力国内医药企业深耕巴基斯坦高增长市场，共绘中巴医药产业互利共赢新蓝图。
China-Pakistan Business Conference on Pharmaceuticals, Healthcare, and Biotechnology Held in Beijing
On the afternoon of June 18, the China-Pakistan Business Conference on Pharmaceuticals, Healthcare, and Biotechnology was held at the Embassy of Pakistan in China. Organized by the Embassy of Pakistan in China and co-hosted by China Overseas Development Association (CODA), the event featured remarks by H.E. Khalil Hashmi, Ambassador of Pakistan to China, and Jiang Yun, Executive Deputy Secretary-General of CODA.
This embassy-exclusive conference offered strong authority and precise matchmaking, enabling enterprises to access firsthand official policy insights and market data from Pakistan in one centralized setting. Leveraging the efficient platform facilitated by CODA, participating companies not only effectively reduced the costs of expanding overseas but also significantly boosted their confidence in investment. Moving forward, CODA will closely follow up on various cooperation intentions, supporting domestic pharmaceutical enterprises in deepening their presence in Pakistan’s high-growth market and jointly advancing a new blueprint for mutually beneficial cooperation between the Chinese and Pakistani pharmaceutical industries.